Skip to main content

Table 1 Description of participating pathology laboratories

From: RAS testing practices and RAS mutation prevalence among patients with metastatic colorectal cancer: results from a Europe-wide survey of pathology centres

Variable (n)

Criterion

Frequency

%

Estimated number of patients with mCRC tested per year (n = 96)

>80

69

71.9

≤80

27

28.1

Reported indication for RAS mutation testing (n = 95)

“On request from an oncologist”

85

89.5

“All CRC patients tested”

5

5.3

“Other”a

5

5.3

Location of RAS mutation testing (n = 96)

Own institution

90

93.8

External

1

1.0

Own institution and external

5

5.2

Minimum percentage of neoplastic cells required (n = 96)

No cut-off defined

10

10.4

<10 %

18

18.8

≥10 %

68

70.8

DNA extraction method used (n = 96)

QIAamp DNA FFPE kit (Qiagen)

40

41.7

Cobas DNA Sample Preparation kit (Roche)

12

12.5

QIAamp DNA mini kit (Qiagen)

7

7.3

Raw proteinase K lysate

6

6.3

Maxwell 16 (Promega)

14

14.6

MagNA Pure (Roche)

1

1.0

Other

16

16.7

RAS mutations tested (n = 96)

All codons tested

70

72.9

Not all codons tested

26

27.1

  1. a“Other” reported indications for RAS testing were: “All stage III & IV CRC patients are tested”, “In our hospital, all CRC patients are tested. Referrals from other centres are tested on demand from the oncologist”, “Diagnostic combination”, “On request from an oncologist as well as in known metastatic (M1) CRC patients” and “Requested by oncologist and pathologist”. CRC colorectal cancer, mCRC metastatic CRC